exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087604 RNA Name: hsa-miR-105-5p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 152394458 End Site(bp): 152394480 External Links: hsa-miR-105-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ARPP19 chr15 52547045 52569883 - DNAJB6 chr7 157335381 157417439 + EXTL2 chr1 100872372 100895179 - GTF2H5 chr6 158168350 158199344 + LMBR1 chr7 156668946 156893216 - MAPKAPK2 chr1 206684944 206734283 + MCL1 chr1 150574551 150579738 - MEF2D chr1 156463727 156500779 - NRIP1 chr21 14961235 15065936 - PDPR chr16 70113626 70162537 + PIK3R3 chr1 46040140 46133036 - PYGB chr20 25248085 25298012 + RAB22A chr20 58309715 58367507 + SLC31A1 chr9 113221544 113264492 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0000987 chr2 30748452 30756180 + hsa_circ_0001414 chr4 56277780 56284152 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC068768.1 chr12 123262060 123262402 + AC079781.5 chr7 97851688 97972985 - AC145207.5 chr17 81878425 81881106 - CYTOR chr2 87454781 87636740 + EPB41L4A-AS1 chr5 112160526 112164818 + FGD5-AS1 chr3 14920347 14948424 - GAS5 chr1 173858559 173868882 - HCG11 chr6 26521709 26527404 + MALAT1 chr11 65497688 65506516 + MCF2L-AS1 chr13 112967484 112968824 - MIR4435-2HG chr2 111006015 111523376 - NNT-AS1 chr5 43571594 43603230 - NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + SCAMP1-AS1 chr5 78342365 78360507 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.